Steven Murphy
Internal Medicine · Stamford, CTNPI 1962623165
Payments from drug & device makers
Across 95 payments — averaging $25.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cepheid$638
- AbbVie$304
- CSL Behring$296
- Novo Nordisk$133
- AstraZeneca$116
- Amarin Pharma, Inc.$103
- plus $807 from 24 others
What the payments were for
- Consulting fees$63827%
- Food & beverage$1,75873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cepheid | 1 | $638 |
| AbbVie(2 entities) | 15 | $304 |
| CSL Behring | 14 | $296 |
| Novo Nordisk | 8 | $133 |
| AstraZeneca | 8 | $116 |
| Amarin Pharma, Inc. | 5 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $102 |
| Bausch Health US, LLC | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| Lilly USA, LLC | 4 | $59 |
| Antares Pharma, Inc. | 2 | $49 |
| Eisai Inc. | 2 | $41 |
| Indivior Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $39 |
| Hikma Pharmaceuticals USA | 2 | $37 |
| MDD US Operations, LLC | 2 | $32 |
| Verona Pharma, Inc. | 1 | $28 |
| Medline Industries LP | 1 | $27 |
| Pfizer | 1 | $23 |
| Invivyd Inc | 1 | $21 |
| Amgen | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Biodelivery Sciences International, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Vivus LLC | 1 | $18 |
| Novartis | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
| Biofire Diagnostics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENEXPERT$638
How this compares
$2,396 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 40 | $42,816 |
| Solu-CortefHydrocortisone Sodium Succ/Pf | 32 | $18,926 |
| Testosterone | 15 | $3,549 |
| Sodium Chloride0.9 % Sodium Chloride | 35 | $1,662 |
| Metformin Hcl | 23 | $244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $59 | $42,81640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Stamford
- David RadinStamford$7M
- Scott GottliebStamford$508K
- Joseph SouferWaterbury$21.5M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.